These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32966155)

  • 1. Preparatory phase for clinical trials of COVID-19 vaccine in Nepal.
    Gupta GP; Shah Y; Pant DK; Lekhak S; Shahi R; Mandal A; Poudel P; Dumre SP; Pandey K; Pandey BD
    Hum Vaccin Immunother; 2021 Feb; 17(2):418-419. PubMed ID: 32966155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 - Important considerations for developing and using a vaccine.
    Rahman IU; Ali N; Ijaz F; Afzal A; Abd Allah EF
    Hum Vaccin Immunother; 2021 Feb; 17(2):414-415. PubMed ID: 32693665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Vaccine Development to Vaccination.
    Pandey A; Belbase P; Parajuli A
    J Nepal Health Res Counc; 2021 Jan; 18(4):807-809. PubMed ID: 33510536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From lockdown to vaccines: challenges and response in Nepal during the COVID-19 pandemic.
    Kansakar S; Dumre SP; Raut A; Huy NT
    Lancet Respir Med; 2021 Jul; 9(7):694-695. PubMed ID: 33932347
    [No Abstract]   [Full Text] [Related]  

  • 5. A million-dose success for Nepal: insights from Nepal's national vaccine deployment plan against COVID-19.
    Bhattarai S; Dhungana J
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33668060
    [No Abstract]   [Full Text] [Related]  

  • 6. Cultural competence in vaccine rollout: migrants would face difficulties accessing covid-19 vaccines.
    Waterman LZ
    BMJ; 2021 Jan; 372():n220. PubMed ID: 33500270
    [No Abstract]   [Full Text] [Related]  

  • 7. How Well the Government of Nepal Is Responding to COVID-19? An Experience From a Resource-Limited Country to Confront Unprecedented Pandemic.
    Rayamajhee B; Pokhrel A; Syangtan G; Khadka S; Lama B; Rawal LB; Mehata S; Mishra SK; Pokhrel R; Yadav UN
    Front Public Health; 2021; 9():597808. PubMed ID: 33681124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiety and depression among people living in quarantine centers during COVID-19 pandemic: A mixed method study from western Nepal.
    B C UB; Pokharel S; Munikar S; Wagle CN; Adhikary P; Shahi BB; Thapa C; Bhandari RP; Adhikari B; Thapa K
    PLoS One; 2021; 16(7):e0254126. PubMed ID: 34242319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces.
    Perosa F; Favoino E; Prete M
    Endocr Metab Immune Disord Drug Targets; 2021; 21(4):567-568. PubMed ID: 33290205
    [No Abstract]   [Full Text] [Related]  

  • 11. Ensuring equitable access to vaccines for refugees and migrants during the COVID-19 pandemic.
    Bartovic J; Datta SS; Severoni S; D'Anna V
    Bull World Health Organ; 2021 Jan; 99(1):3-3A. PubMed ID: 33658728
    [No Abstract]   [Full Text] [Related]  

  • 12. Migrant health is public health: a call for equitable access to COVID-19 vaccines.
    Al-Oraibi A; Martin CA; Hassan O; Wickramage K; Nellums LB; Pareek M
    Lancet Public Health; 2021 Mar; 6(3):e144. PubMed ID: 33640075
    [No Abstract]   [Full Text] [Related]  

  • 13. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Grim Reality of Health System Uncovered with COVID-19 Pandemic in Nepal.
    Nepal R; Bhattarai B
    J Nepal Health Res Counc; 2020 Nov; 18(3):569-571. PubMed ID: 33210663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Considerations for COVID-19 Vaccination of Refugees, Immigrants, and Migrants.
    Thomas CM; Osterholm MT; Stauffer WM
    Am J Trop Med Hyg; 2021 Jan; 104(2):433-435. PubMed ID: 33534734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Covid-19 Vaccines at Pandemic Speed.
    Lurie N; Saville M; Hatchett R; Halton J
    N Engl J Med; 2020 May; 382(21):1969-1973. PubMed ID: 32227757
    [No Abstract]   [Full Text] [Related]  

  • 17. Building Trust in COVID-19 Vaccines and Beyond Through Authentic Community Investment.
    Ojikutu BO; Stephenson KE; Mayer KH; Emmons KM
    Am J Public Health; 2021 Mar; 111(3):366-368. PubMed ID: 33301352
    [No Abstract]   [Full Text] [Related]  

  • 18. How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Shakir S; Lane S; Davies M
    Drug Saf; 2021 Jan; 44(1):1-5. PubMed ID: 33219926
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.
    CDC COVID-19 Vaccine Breakthrough Case Investigations Team
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(21):792-793. PubMed ID: 34043615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Exposure Characteristics and the Risk for COVID-19 Infection Among Health Care Workers With and Without BNT162b2 Vaccination.
    Oster Y; Benenson S; Yochi Harpaz L; Buda I; Nir-Paz R; Strahilevitz J; Cohen MJ
    JAMA Netw Open; 2021 Sep; 4(9):e2125394. PubMed ID: 34468758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.